We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+5.04%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$6.97B
AUM Growth
-$106M
Cap. Flow
-$271M
Cap. Flow %
-3.88%
Top 10 Hldgs %
34.81%
Holding
187
New
15
Increased
42
Reduced
87
Closed
11

Top Buys

Rank Stock Value
1
RVMD icon
Revolution Medicines
RVMD
+$28.5M
2
CLDX icon
Celldex Therapeutics
CLDX
+$26.8M
3
EXAS
Exact Sciences
EXAS
+$15.3M
4
TNDM icon
Tandem Diabetes Care
TNDM
+$13.7M
5
CRL icon
Charles River Laboratories
CRL
+$6.89M

Top Sells

Rank Stock Value
1
RDUS
Radius Health, Inc.
RDUS
+$91.2M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$38.7M
3
SWAV
Shockwave Medical, Inc. Common Stock
SWAV
+$24M
4
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$19.3M
5
AXSM icon
Axsome Therapeutics
AXSM
+$16M

Sector Composition

Rank Sector Weight
1 Healthcare 99.34%
2 Industrials 0.59%
3 Energy 0.02%
4 Communication Services 0.01%
5 Technology 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRK icon
151
Merck
MRK
$307B
$417K 0.01%
4,844
+3,880
+402% +$346K
GDX icon
152
VanEck Gold Miners ETF
GDX
$21.6B
$323K ﹤0.01%
13,400
– –
EL icon
153
Estee Lauder
EL
$30.3B
$291K ﹤0.01%
1,348
– –
OPT
154
DELISTED
Opthea Limited American Depositary Shares
OPT
$283K ﹤0.01%
47,000
– –
SWKS icon
155
Skyworks Solutions
SWKS
$8.99B
$179K ﹤0.01%
2,100
– –
MCHI icon
156
iShares MSCI China ETF
MCHI
$6.12B
$174K ﹤0.01%
4,100
– –
GDXJ icon
157
VanEck Junior Gold Miners ETF
GDXJ
$6.62B
$147K ﹤0.01%
5,000
– –
MKTX icon
158
MarketAxess Holdings
MKTX
$4.08B
$147K ﹤0.01%
662
– –
MELI icon
159
Mercado Libre
MELI
$92.9B
$141K ﹤0.01%
170
– –
AVLR
160
DELISTED
Avalara, Inc.
AVLR
$119K ﹤0.01%
1,300
– –
JMIA
161
Jumia Technologies
JMIA
$784M
$105K ﹤0.01%
18,000
– –
DLB icon
162
Dolby
DLB
$4.79B
$104K ﹤0.01%
1,600
– –
IPGP icon
163
IPG Photonics
IPGP
$4.16B
$89K ﹤0.01%
1,050
– –
ACHC icon
164
Acadia Healthcare
ACHC
$3.17B
$71K ﹤0.01%
+906
New +$72.4K
UTHR icon
165
United Therapeutics
UTHR
$22.5B
$63K ﹤0.01%
301
+108
+56% +$24.1K
CAH icon
166
Cardinal Health
CAH
$52.9B
$61K ﹤0.01%
+918
New +$58.2K
TSM icon
167
TSMC
TSM
$2.09T
$53K ﹤0.01%
+770
New +$63.6K
NKTR icon
168
Nektar Therapeutics
NKTR
$2.19B
$47K ﹤0.01%
987
-933
-49% -$55.5K
ZTS icon
169
Zoetis
ZTS
$31.9B
$36K ﹤0.01%
246
-257
-51% -$43K
CTLT
170
DELISTED
CATALENT, INC.
CTLT
$34K ﹤0.01%
+473
New +$47K
ASR icon
171
Grupo Aeroportuario del Sureste
ASR
$8.23B
$27K ﹤0.01%
135
– –
NVST icon
172
Envista
NVST
$4.33B
$27K ﹤0.01%
822
+338
+70% +$12.8K
EQIX icon
173
Equinix
EQIX
$100B
$23K ﹤0.01%
40
– –
EVTC icon
174
Evertec
EVTC
$1.89B
$23K ﹤0.01%
739
– –
INFY icon
175
Infosys
INFY
$45.8B
$20K ﹤0.01%
1,130
– –
4 5 6
7
8

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q3 2022 Portfolio in Review

As of Q3 2022, Bellevue Group held 187 positions worth $6.97B, down 1.5% from $7.07B the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Bellevue Group withdrew a net $271M in Q3 2022, closing 11 positions and reducing 87 holdings. Its most notable exit was Radius Health, Inc., an estimated $91.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 98% a quarter earlier, followed by Industrials and Energy.

Against the trend, Bellevue Group opened a new position in Zai Lab worth $1.28M.

  • Bellevue Group's largest Q3 2022 buy was Zai Lab: 36,600 shares worth $1.28M.
  • Bellevue Group added most to Revolution Medicines in Q3 2022, an estimated $28.5M increase.
  • Bellevue Group's biggest Q3 2022 reduction was Sarepta Therapeutics, cutting an estimated $38.7M.
  • Bellevue Group fully exited Radius Health, Inc. in Q3 2022, selling an estimated $91.2M.
  • Bellevue Group's ten largest holdings make up 35% of its $6.97B portfolio in Q3 2022.
  • Bellevue Group opened 15 new positions and closed 11 in Q3 2022.
  • Bellevue Group's portfolio value fell 1.5% quarter-over-quarter to $6.97B.

Based on Bellevue Group's 13F filing for Q3 2022, filed 14 Nov 2022.